NASDAQ:BLRX
BioLineRx Ltd. Stock News
$1.12
+0.0100 (+0.90%)
At Close: Mar 28, 2024
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
02:56pm, Wednesday, 15'th Jan 2020
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
12:00am, Wednesday, 15'th Jan 2020BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe
12:46pm, Tuesday, 14'th Jan 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced that the European Commission (EC) has granted Orphan Drug Designation to its
BioLineRx Receives Orphan Drug Designation For Motixafortide (BL-8040) For Treatment Of Pancreatic Cancer In Europe
12:00am, Tuesday, 14'th Jan 2020BioLineRx to Present at the 2020 Biotech Showcase
12:00pm, Wednesday, 08'th Jan 2020
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management will provide a corporate update at the 2020 Biotech Showcase
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today updated data from the triple combination arm of the ongoing Phase 2a COMBAT/